Acadia Pharmaceuticals target price cut to $34 from $36
ACAD•BMO cut its target price for Acadia Pharmaceuticals to $34 from $36.
Related News
BlackRock cuts Abivax stake below 5%, voting rights to 4.52%
ABVX•
Charles River Laboratories: Deutsche Bank raises target price to $320 from $300
CRL•
JPMorgan Chase crosses 5% stake threshold in Soitec, holds 5.04% of capital
JPM•
Firefly Neuroscience partners with NeuroSigma to broaden access to Monarch eTNS pediatric ADHD therapy
AIFF•
Cerenome unit CNSide Diagnostics sets Sept. 30 CNSide business update call
CNSY•